3 Anti-Xa Viva and Flashcards
Recall, application and common traps
3.1 Viva questions with model answers
3.1.1 “Explain the principle of the anti-Xa assay.”
The patient’s plasma is exposed to a known excess of factor Xa. Anticoagulant in the sample inhibits some Xa. Residual Xa cleaves a chromogenic substrate, generating colour. The signal is inversely related to anticoagulant effect and is converted to a result using a drug-appropriate calibration curve.
3.1.2 “Why can anti-Xa be preferable to APTT for UFH monitoring?”
APTT is influenced by reagent sensitivity and by patient factors including lupus anticoagulant, factor deficiency, DIC and acute-phase factor VIII elevation. Anti-Xa more directly reflects Xa inhibition by heparin, although it has its own calibration, specimen and interference limitations.
3.1.3 “A patient was switched from apixaban to UFH and has a high anti-Xa result soon after the infusion begins. What is the explanation?”
Residual apixaban can inhibit Xa in the heparin-calibrated assay and falsely suggest excessive UFH effect. Confirm recent drug exposure, consider a baseline heparin-calibrated anti-Xa before UFH where feasible, and use the laboratory’s validated transition protocol.
3.1.4 “Can you use a heparin-calibrated anti-Xa result to quantify apixaban?”
No. It may detect Xa inhibition, but a precise apixaban concentration needs an apixaban-calibrated assay or another locally validated method.
3.1.5 “What makes an LMWH anti-Xa result uninterpretable?”
No documented last dose or sampling time, inappropriate peak/trough comparison, an incorrect calibrator, inappropriate sample handling, or interpretation without knowing the LMWH preparation and indication.
3.2 Rapid-recall cards
Tap a card to reveal the answer. Tap again to test yourself once more.
3.3 Mini-case: act before you titrate
Case. A patient with pulmonary embolism was given apixaban until this morning and is now on IV UFH. Two hours later, the heparin-calibrated anti-Xa is 1.1 IU/mL. There is no bleeding.
Best response. Do not assume UFH overdose. The recent apixaban can elevate the anti-Xa result. Confirm drug timing, discuss with the laboratory, and follow the locally validated UFH-after-DOAC transition pathway. APTT may be the temporary monitoring strategy in some centres, but only within local guidance.
An answer that simply says “hold UFH because anti-Xa is high” misses the key laboratory issue. High marks come from identifying the possible interference first.